These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 10370911

  • 1. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
    Melamed E, Zoldan J, Galili-Mosberg R, Ziv I, Djaldetti R.
    J Neural Transm Suppl; 1999; 56():173-83. PubMed ID: 10370911
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J, Stacy M.
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
    Deleu D, Northway MG, Hanssens Y.
    Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
    Nyholm D.
    Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
    [Abstract] [Full Text] [Related]

  • 12. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN.
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [Abstract] [Full Text] [Related]

  • 13. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic optimisation in the treatment of Parkinson's disease.
    Contin M, Riva R, Albani F, Baruzzi A.
    Clin Pharmacokinet; 1996 Jun; 30(6):463-81. PubMed ID: 8792058
    [Abstract] [Full Text] [Related]

  • 15. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Jun; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.